A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer

Abstract Background Antiangiogenic treatment and immunochemotherapy effectively treat patients with advanced esophageal cancer. However, there remains a dearth of studies concerning neoadjuvant therapy for resectable esophageal cancer. Methods The study focused on patients with T2–4NxM0 resectable e...

Full description

Bibliographic Details

Published in:	Thoracic Cancer
Main Authors:	Hongtao Duan, Zhaoyang Wang, Lili Cao, Yifang Zhu, Liping Tong, Xiaolong Yan
Format:	Article
Language:	English
Published:	Wiley 2024-07-01
Subjects:	antiangiogenic chemotherapy neoadjuvant treatment resectable esophageal cancer sintilimab
Online Access:	https://doi.org/10.1111/1759-7714.15312